Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Amy Guan

Nurse Practitioner, Gerontology Saint Louis, MO Nurse Practitioner

NPI 1801398813 CMS profile 10515721

12348 Old Tesson Rd Ste 250, Saint Louis, MO 63128

Open in the dashboard

General payments

$4,872

272 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Guan of Saint Louis, MO is reported in the CMS Open Payments database as having received $4,872 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,126 129
2024 General $2,271 116
2023 General $475 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Guan
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Amy Guan were reported at $2,126. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Amy Guan Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $475 $158 $53–$482 $160
2024 $2,271 $171 $55–$533 $164
2025 $2,126 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Lilly USA, LLC $812 46 payments
  2. AstraZeneca Pharmaceuticals LP $802 39 payments
  3. Novo Nordisk Inc $567 31 payments
  4. Amgen Inc. $374 23 payments
  5. Otsuka America Pharmaceutical, Inc. $357 20 payments
  6. AbbVie, Inc. $255 13 payments
  7. Lundbeck LLC $219 14 payments
  8. Pfizer Inc. $205 16 payments
  9. Sumitomo Pharma America, Inc. $124 6 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $116 6 payments
  11. Other $1,041 58 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,872 272 payments
Products named General payments · program years 2023–2025
  1. MOUNJARO $718 41 payments
  2. FARXIGA $510 23 payments
  3. REXULTI Psychiatry $357 20 payments
  4. Ozempic $341 18 payments
  5. RYBELSUS $302 16 payments
  6. AIRSUPRA $258 10 payments
  7. BREZTRI $241 10 payments
  8. REXULTI Psychiatry $219 14 payments
  9. Wegovy $198 11 payments
  10. Otezla $182 12 payments
  11. Other $2,785 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,368

Median for Nurse Practitioner: 389

Drug cost

$120,845

Median for Nurse Practitioner: $21,885

Branded share of claims

25.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 25 $35,685
Rexulti Brexpiprazole Brand 17 $25,801
Jardiance Empagliflozin Brand 17 $17,381
Myrbetriq Mirabegron Brand 20 $16,624
Gemtesa Vibegron Brand 14 $12,376
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $1,014
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 98 $861
Mirtazapine Generic 24 $835
Fluticasone Propionate Generic 82 $797
Atorvastatin Calcium Generic 81 $763

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$62,112

Of which drugs: $11,413

Medicare patients

224

Average age 77

Services billed

1,701

131 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Chronic kidney disease 39%
Ischemic heart disease 38%
Depression 38%
Diabetes 33%
Atrial fibrillation 29%
Heart failure 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 23 23 $1,872

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $344
$344 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $251
$251 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $144
  • Lundbeck LLC $38
$182 17 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $115
$115 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record